Skip to content
Menu

ProQR Therapeutics To Present Data On Its AX-0810, AX-0811 At The Liver Meeting 2026, Nature Conferences RNA

Benzinga Newsdesk 3 weeks ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform,

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced upcoming presentations highlighting clinical and preclinical progress with AX-0810 and AX-0811 and the broader Axiomer RNA editing platform at TIDES Europe, The Liver Meeting 2026, Nature Conferences RNA at the Bench and Bedside V. 

Read at benzinga.com

← All stock news